Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

645 public trials 88 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Active, Not Recruiting

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

NCT04333524

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • CHU de Dijon Dijon, France
  • Saint Louis Hospital Paris, France
  • IUCT Oncopole Toulouse Toulouse, France
  • ASO SS. Antonio e Biagio e C. Arrigo Alessandria, AL, Italy
View all 25 locations
View Trial Details
Active, Not Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • Ucsf Fresno University of California San Francisco Fresno Fresno, California, United States
  • Kaiser Permanente Southern California Irvine, California, United States
  • Cancer and Blood Specialty Clinic Los Alamitos, California, United States
  • Los Angeles Cancer Network Los Angeles, California, United States
View all 270 locations
View Trial Details
Active, Not Recruiting

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

NCT04212013

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • George Washington Cancer Center Washington D.C., District of Columbia, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
View Trial Details
Active, Not Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

NCT04799275

Conditions
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, +30 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Downey, California, United States
  • Research Site Duarte, California, United States
  • Research Site Fountain Valley, California, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824

Conditions
Chronic Disease, Diffuse Large B Cell Lymphoma, Disease Attributes, +25 more
Locations
  • Tohoku University Hoaspital Sendai, Miyagi, Japan
  • Aichi Cancer Center Hospital Aichi, Japan
  • NHO Nagoya Medical Center Aichi, Japan
  • National Cancer Center Hospital East Chiba, Japan
View all 15 locations
View Trial Details
Active, Not Recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037

Conditions
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Chronic Disease, DLBCL, +26 more
Locations
  • Arizona Mayo Clinic Phoenix, Arizona, United States
  • University of California at San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 85 locations
View Trial Details
Active, Not Recruiting

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT04416451

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Cancer Center (Data collection only) Duarte, California, United States
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol Activities) Montvale, New Jersey, United States
View Trial Details

Related conditions